摘要
目的研究沙美特罗/丙酸氟替卡松对稳定期慢性阻塞性肺疾病(COPD)患者疗效及N末端脑钠肽前体(NT-ProBNP)、中性粒细胞/淋巴细胞比值(NLR)的影响。方法选取2017年12月—2019年12月在张家口市第一医院接受治疗的120例稳定期COPD,根据治疗方法的不同分为观察组和对照组各60例。对照组予常规治疗,观察组在对照组基础上加用沙美特罗/丙酸氟替卡松雾化吸入治疗,疗程均为12周。比较2组临床疗效,治疗前后心肺功能[第1秒用力呼气容积(FEV1)、第1秒用力呼气容积/用力肺活量(FEV1/FVC)、6 min步行试验(6MWT)],治疗前后心肌损伤标志物及炎性因子[N末端脑钠肽前体(NT-proBNP)、Clara细胞分泌蛋白-16(CC-16)、NLR]水平及治疗期间不良反应发生率。结果观察组治疗总有效率高于对照组(P<0.05)。治疗后,2组FEV1、FEV1/FVC、6MWT水平均升高,NT-proBNP、NLR、CC-16水平显著降低,且观察组上述指标改善程度均大于对照组(P<0.05,P<0.01)。2组治疗期间不良反应总发生率比较差异无统计学意义(P>0.05)。结论沙美特罗/丙酸氟替卡松能明显改善稳定期COPD患者NT-proBNP、NLR水平,提高临床疗效,且安全性高。
Objective To study clinical efficacy of Salmeterol/Fluticasone Propionate in treatment of patients with stable chronic obstructive pulmonary disease(COPD)and its effects on N-terminal pro-brain natriuretic peptide(NT-proBNP)and neutrophil/lymphocyte ratio(NLR).Methods A total of 120 patients with stable COPD admitted between December 2017 and December 2019 were selected and divided into observation group(n=60)and control group(n=60)according to different therapeutic methods.Control group was treated with routine treatment,while observation group was added with Salmeterol/Fluticasone Propionate atomization inhalation on the basis of treatment for control group.The course of treatment was 12 weeks.Clinical efficacy,cardiopulmonary functions[forced expiratory volume in one second(FEV1),FEV1/forced vital capacity(FEV1/FVC),6-min walk test(6MWT)],levels of myocardial injury markers and inflammatory factors[NT-proBNP,Clara cell secretory protein-16(CC-16),NLR]before and after treatment,and incidence rate of adverse reactions during the treatment were compared between two groups.Results The total effective rate in observation group was significantly higher than that in control group(P<0.05).After treatment,levels of FEV1,FEV1/FVC and 6MWT were significantly increased,while levels of NT-proBNP,NLR and CC-16 were significantly decreased in two groups;the improvement degrees of the above indexes in observation group were more obvious than those in control group(P<0.05,P<0.01).There was no significant difference in the total incidence rate of adverse reactions between two groups(P>0.05).Conclusion Salmeterol/Fluticasone Propionate may significantly improve levels of NT-proBNP and NLR and improve clinical efficacy with good safety in treatment of patients with stable COPD.
作者
高岩
赵晓倩
关艳红
苏海燕
王倩
曹文娟
岳燕军
韩宝勇
GAO Yan;ZHAO Xiao-qian;GUAN Yan-hong;SU Hai-yan;WANG Qian;CAO Wen-juan;YUE Yan-jun;HAN Bao-yong(Department of Clinical Laboratory,the First Hospital of Zhangjiakou,Zhangjiakou,Hebei 075000,China;Department of Respiratory Diseases and Critical Care,the First Hospital of Zhangjiakou,Zhangjiakou,Hebei 075000,China;Department of Pharmacy,Maternal and Child Health Hospital of Shijiazhuang,Shijiazhuang 050000,China;Department of Clinical Laboratory,the Fourth People's Hospital of Hengshui,Hengshui,Hebei 053000,China)
出处
《解放军医药杂志》
CAS
2022年第3期81-84,共4页
Medical & Pharmaceutical Journal of Chinese People’s Liberation Army
基金
河北省医学科学研究重点课题计划项目(20211224)。
关键词
肺疾病
慢性阻塞性
稳定期
沙美特罗
丙酸氟替卡松
肺活量
N末端脑钠肽前体
Pulmonary disease,chronic obstructive
Stable period
Salmeterol
Fluticasone propionate
Vital capacity
N-terminal pro brain natriuretic peptide
